Posts in the “Clinical Trials Clinical Trials” category:

Ellen Sigal and Jeff Allen Named September LUNGevity Heroes for Lung-MAP Creation

Posted by Samantha Powell on September 23rd, 2014 |

The LUNGevity Foundation has announced that Ellen Sigal, Friends of Cancer Research Chairperson and Founder, and Executive Director Jeff Allen, PhD, were recently distinguished as the September LUNGevity Heroes for the work they have done advocating for policies to improve health outcomes and cancer care, and for being responsible for the creation of groundbreaking initiatives […]

Yale study sees benefits of traditional lung cancer surgery

Posted by Samantha Powell on September 17th, 2014 |

Traditional surgery appears to save lives better than radiosurgery, even though it’s more invasive, when treating early-stage non-small cell lung cancer, according to Yale University. A study of 1,078 lung cancer patients’ Medicare billing records showed this to be true even considering the risks of regular surgery. “What was dramatic to me was the relatively […]

Treatment For Lung Cancer May Depend On Your DNA

Posted by Samantha Powell on September 16th, 2014 |

The Northside Hospital Cancer Institute (NHCI), Atlanta, has announced it will participate in a unique National Cancer Institute clinical collaboration to treat lung cancer based on a patient’s genetic profile, becoming the first to offer the clinical trial known as Lung-MAP. The study is a multi-drug, multi-arm, biomarker-driven clinical trial for patients with advanced squamous […]

Online Screening for Rare Lung Cancer Mutation Opens Door to New Kind of Clinical Trial

Posted by Samantha Powell on August 22nd, 2014 |

In the previous few years, several breakthrough treatments have become available for key subtypes of lung cancer. Patients who may benefit from these treatments can be pre-identified by looking for defined genetic abnormalities in their cancer. For example, patients whose lung cancer is driven by rearrangement of the gene ALK derive significant benefit from the […]

NCI Launches Molecular Medicine Clinical Trials; Response Genetics Nabs Profiling Contract

Posted by Samantha Powell on August 18th, 2014 |

The National Cancer Institute said today it has launched new clinical trials that will use tumor sequencing and genetic markers to help determine whether therapies targeting genetic alterations can prevent lung cancer recurrence. Separately, Response Genetics said it has been awarded a “multi-million dollar” subcontract from Leidos Biomedical Research, a contractor for the NCI-sponsored Frederick […]

Ambitious Lung-MAP Trial Launched With Five Novel Drugs

Posted by Samantha Powell on August 1st, 2014 |

Five novel agents for the treatment of patients with advanced squamous cell carcinoma of the lung will be evaluated in the recently launched Lung-MAP trial, an innovative biomarker-driven study that aims to improve the drug development process while exploring therapeutic options for this challenging malignancy. Plans call for enrolling up to 5000 patients through more […]

Possible Advance for Some Late-Stage Lung Cancer Patients

Posted by Samantha Powell on July 8th, 2014 |

Surgical biopsy is safe for certain late-stage lung cancer patients and could improve their chances of getting treated with newer types of drugs that target cancer-related genetic mutations, a new small study reveals. In many cases, surgical biopsy is too dangerous for these patients, so less-invasive methods are used, including fine-needle aspiration and core needle […]

Is It Time To Ask a Disturbing Question About The Geographical Location of Cancer Clinical Trials?

Posted by Samantha Powell on June 25th, 2014 |

The genesis of this commentary is the recent publication of population-based survival outcomes associated with specific malignancies in various European countries.1 This analysis, which covered the years 1999 to 2007 revealed rather striking variation in the survival of patients with the specific cancers based on geographical location. For example, five-year survival in the United Kingdom […]

New study aims to rapidly test lung cancer drugs

Posted by Samantha Powell on June 16th, 2014 |

A bold new way to test cancer drugs started Monday in hundreds of hospitals around the U.S. In a medical version of speed dating, doctors will sort through multiple experimental drugs and match patients to the one most likely to succeed based on each person’s unique tumor gene profile. It’s a first-of-a-kind experiment that brings […]

Amgen Joins National Cancer Institute, Other Companies On Lung-MAP Project

Posted by Samantha Powell on June 16th, 2014 |

Amgen announced that it will collaborate with the National Cancer Institute and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. In the U.S., […]